DrugPatentWatch Database Preview

TYGACIL Drug Profile

see a sample report or, see our see our flat-rate plans

Which patents cover Tygacil, and when can generic versions of Tygacil launch?

Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tigecycline profile page.

Summary for TYGACIL

US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	73
Clinical Trials:	5
Patent Applications:	1,421
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TYGACIL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYGACIL
DailyMed Link:	TYGACIL at DailyMed

Drug patent expirations by year for TYGACIL

Pharmacology for TYGACIL

Ingredient-type	Tetracyclines
Drug Class	Tetracycline-class Antibacterial

Synonyms for TYGACIL

(4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide
(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
(4S,4aS,5aR,12aS)-9-(2-(tert-Butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1
(4S,4AS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxa
(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aS)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
(4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
121GE002
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-[[[(1,1-DIMETHYLETHYL)AMINO]ACETYL]AMINO]-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[2-[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
220620-09-7
220620-09-7 (anhy.)
620T097
70JE2N95KR
9-t-Butylglycylamido minocycline
9-t-Butylglycylamido-minocycline hydrate
9-tert-Butylglycylamidominocycline
A5226
AB0011463
AB01566818_01
AB2000089
AC-1798
AC1NQZEU
AC1O714W
ACT08710
AK-73038
AKOS015895663
AKOS025401452
AM20090708
AN-6306
BC677670
BCPP000045
BR-73038
C12012
C29H39N5O8
CAS-220620-09-7
CHEBI:149836
CHEMBL376140
CS-1876
CT0198
D01079
D0G4OD
DB00560
DSSTox_CID_28507
DSSTox_GSID_48581
DSSTox_RID_82779
DTXSID2048581
FPZLLRFZJZRHSY-HJYUBDRYSA-N
FT-0657279
GAR 936
GAR-936
GAR-936,Tigecycline
Glycylcycline
HY-B0117
I06-1089
LS-186580
LS-187002
LS-187782
MFCD00935753
MLS006010079
MolPort-009-199-379
MolPort-028-751-260
N-((5aR,6aS,7S,10aS,Z)-9-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl)-2-(tert-butylamino)acetamide
N-[(5aR,6aS,7S,9E,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
N-[(5AR,6AS,7S,9Z,10AS)-9-[AMINO(HYDROXY)METHYLIDENE]-4,7-BIS(DIMETHYLAMINO)-1,10A,12-TRIHYDROXY-8,10,11-TRIOXO-5,5A,6,6A,7,8,9,10,10A,11-DECAHYDROTETRACEN-2-YL]-2-(TERT-BUTYLAMINO)ACETAMIDE
N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
NCGC00183095-01
PL010867
PL050681
PubChem21336
Q-101396
RL02680
S-5066
s1403
SC-20200
SCHEMBL101795
SCHEMBL105082
SCHEMBL237962
SMR002530064
SOVUOXKZCCAWOJ-HJYUBDRYSA-N
ST2413997
SYN3024
TBG-MINO
Tigeciclina
Tigecyclin
Tigecycline
Tigecycline (JAN/USAN)
Tigecycline [USAN:INN:BAN]
Tigecycline [USAN]
Tigecycline hydrate
Tigecycline, Antibiotic for Culture Media Use Only
Tigecyclinum
Tigilcycline
Tox21_112910
Tygacil (TN)
Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline
Tygacil;GAR-936;WAY-GAR-936;TBG-MINO
Tygacil(TM)
UNII-70JE2N95KR
WAY-GAR-936
ZINC100022633
ZINC102200515
ZINC14879972

US Patents and Regulatory Information for TYGACIL

+ Get email alerts for changes to this table

Glossary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes	➤ Try a Free Trial	➤ Try a Free Trial	Y			➤ Try a Free Trial
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes	➤ Try a Free Trial	➤ Try a Free Trial	Y			➤ Try a Free Trial
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes	➤ Try a Free Trial	➤ Try a Free Trial	Y			➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

see a sample report or, see our see our flat-rate plans

Expired US Patents for TYGACIL

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	➤ Try a Free Trial	➤ Try a Free Trial
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	➤ Try a Free Trial	➤ Try a Free Trial
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for TYGACIL

Drugname	Dosage	Strength	RLD	Date
➤ Subscribe	For Injection	50 mg per vial	➤ Subscribe	➤ Try a Free Trial

see a sample report or, see our see our flat-rate plans

International Patents for TYGACIL

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Honduras	2006011218	➤ Try a Free Trial
European Patent Office	1858488	➤ Try a Free Trial
Costa Rica	9416	➤ Try a Free Trial
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for TYGACIL

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
06/030	Ireland	➤ Try a Free Trial	PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
C0031	France	➤ Try a Free Trial	PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424
00244	Netherlands	➤ Try a Free Trial	PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Summary for TYGACIL

Pharmacology for TYGACIL

Synonyms for TYGACIL

Paragraph IV (Patent) Challenges for TYGACIL

For more information try a trial or see the plans and pricing